Skip to main content
SpringerLink
Log in

Wirkmechanismen der intravesikalen BCG-Immuntherapie des oberflächlichen Harnblasenkarzinoms

Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer

  • AUO
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Immuntherapeutische Ansätze zur Bekämpfung solider Tumorerkrankungen haben bislang zumeist nur experimentellen Charakter. Lediglich die intravesikale Immuntherapie mit Bacillus-Calmette-Guérin (BCG) des oberflächlichen Harnblasenkarzinoms stellt die einzige Ausnahme dar, ist sie doch der topischen Chemotherapie klar überlegen und weltweit klinisch etabliert. Daher wird BCG als die zzt. erfolgreichste Immuntherapie angesehen. Der genaue Wirkmechanismus ist jedoch noch nicht vollständig bekannt. Wir geben hier einen aktuellen Überblick zum komplexen Forschungsbereich des Wirkmechanismus dieser Therapie.

Abstract

Immunotherapy for treatment of solid cancer mostly is an experimental treatment. In contrast, intravesical immunotherapy of superficial bladder cancer with bacille Calmette-Guérin (BCG) is clinically well established and accepted worldwide because of better results compared to topical chemotherapy. BCG is currently regarded as the most successful immunotherapy of cancer. Unfortunately the mechanism of action has not yet been fully clarified. This article gives an overview on the complex research on the mechanisms of actionhighly successful therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Arnold J, de Boer EC, O’Donnell MA et al. (2004) Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma. J Immunother 27: 116–123

    Article  PubMed  Google Scholar 

  2. Behr MA, Wilson MA, Gill WP et al. (1999) Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284: 1520–1523

    Article  PubMed  Google Scholar 

  3. Böhle A, Gerdes J, Ulmer AJ et al. (1990) Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144: 53–58

    PubMed  Google Scholar 

  4. Böhle A, Busemann E, Gerdes J et al. (1990) Elevations of cytokines interleukin-1, interleukin-2, and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J Urol 144: 59–64

    PubMed  Google Scholar 

  5. Brandau S, Suttmann H, Riemensberger J et al. (2000) Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guerin-activated killer cells. Clin Cancer Res 6: 3729–3738

    PubMed  Google Scholar 

  6. Brandau S, Riemensberger J, Böhle A et al. (2001) NK cells are essential for effective BCG immunotherapy. Int J Cancer 92: 697–702

    Article  PubMed  Google Scholar 

  7. Brandau S, Bohle A (2001) Activation of natural killer cells by Bacillus Calmette-Guerin. Eur Urol 39: 518–524

    Article  PubMed  Google Scholar 

  8. Chapman PB, Houghton AN (1993) Non-antibody immunotherapy of cancer. Curr Opin Immunol 5: 726–731

    Article  PubMed  Google Scholar 

  9. ChenX, LuoY, YamadaH, O’Donnell MA (2001) BCG potentiates human chemokine induction in vivo and in vitro. J Urol A 165: 465

    Google Scholar 

  10. Chin JL, Kadhim SA, Batislam E et al. (1996) Mycobacterium cell wall: an alternative to intravesical Bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer. J Urol 156: 1189–1193

    Article  PubMed  Google Scholar 

  11. Clinton SK, Canto E, O’Donnell MA (2000) Interleukin-12. Opportunities for the treatment of bladder cancer. Urol Clin North Am 27: 147–155

    Article  PubMed  Google Scholar 

  12. de Boer EC, de Jong WH, van der Meijden AP et al. (1991) Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res 19: 45–50

    Article  PubMed  Google Scholar 

  13. de Boer EC (1992) Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumor necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother 34: 306–312

    Article  PubMed  Google Scholar 

  14. de Boer EC (1997) Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res 25: 31–34

    Article  PubMed  Google Scholar 

  15. de Reijke TM Vos PCN, de Boer EC et al. (1993) Cytokine production by the human bladder carcinoma cell line T24 in the presence of Bacillus Calmette-Guérin. Urol Res 21: 349–352

    Article  PubMed  Google Scholar 

  16. Esuvaranathan K (1995) Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J Urol 154: 572–575

    Article  PubMed  Google Scholar 

  17. Gunther JH, Jurczok A, Wulf T et al. (1999) Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res 59: 2834–2837

    PubMed  Google Scholar 

  18. Haaff EO, Catalona WJ, Ratliff TL (1986) Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 136: 970–974

    PubMed  Google Scholar 

  19. Hawkyard SJ, Jackson AM, James K et al. (2005) The inhibitory effects of interferon gamma on the growth of bladder cancer cells. J Urol 147: 1399–1403

    Google Scholar 

  20. Herr HW ,Schwalb DM, Zhang ZF et al. (1995) Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 13: 1404–1408

    PubMed  Google Scholar 

  21. Jackson AM, Alexandroff AB, McIntyre M et al. (1994) Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy. J Clin Pathol 47: 309–312

    PubMed  Google Scholar 

  22. Jackson AM, Prescott S, Hawkyard SJ et al. (1995) Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol 99: 369–375

    PubMed  Google Scholar 

  23. Jackson AM (1998) Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis. J Urol 159: 1054–1063

    Article  PubMed  Google Scholar 

  24. Kaempfer R (1996) Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol 14: 1778–1786

    PubMed  Google Scholar 

  25. Kavoussi LR, Brown EJ, Ritchey, JK, Ratliff TL (1990) Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 85: 62–67

    PubMed  Google Scholar 

  26. Kelley DR, Haaff EO, Becich M et al. (1985) Intravesical bacillus Calmette-Guérin-therapy for superficial bladder cancer: Effect of bacillus Calmette-Guérin viability on treatment results. J Urol 134: 48–53

    PubMed  Google Scholar 

  27. Lage JM, Bauer WC, Kelley DR et al. (1986) Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer. J Urol 135: 916–919

    PubMed  Google Scholar 

  28. Lamm DL ,Crawford ED, Blumenstein BA et al.(1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 325: 1205–1209

    PubMed  Google Scholar 

  29. Lamm DL (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163: 1124–1129

    Article  PubMed  Google Scholar 

  30. Ludwig AT (2004) Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 64: 3386–3390

    Article  PubMed  Google Scholar 

  31. Luo Y, Chen X, Downs T et al. (1999) IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. J Immunol 162: 2399–2405

    PubMed  Google Scholar 

  32. Luo Y, Chen X, Han R, O’Donnell MA (2001) Recombinant bacille Calmette-Guerin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 123: 264–270

    Article  PubMed  Google Scholar 

  33. Luo Y (2004) Recombinant Mycobacterium bovis bacillus Calmette-Guerin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin Exp Immunol 137: 24–34

    Article  PubMed  Google Scholar 

  34. Mahairas GG, Sabo PJ, Hickey MJ et al. (1996) Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 178: 1274–1282

    PubMed  Google Scholar 

  35. Malmstrom PU, Wijkstrom H, Lundholm C et al. (1999) 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161: 1124–1127

    Article  PubMed  Google Scholar 

  36. McAveney KM, Gomella LG, Lattime EC (1994) Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy. Cancer Immunol Immunother 39: 401–406

    Article  PubMed  Google Scholar 

  37. Mendez-Samperio P, Ayala-Verdin HE, Trejo-Echeverria A (1999) Interleukin-12 regulates the production of Bacille Calmette-Guerin-induced interferon-gamma from human cells in a CD40-dependent manner. Scand J Immunol 50: 61–67

    PubMed  Google Scholar 

  38. Mizutani Y, Nio Y, Fukumoto M, Yoshida O (1992) Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer. Cancer 69: 537–545

    PubMed  Google Scholar 

  39. Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116: 180–183

    PubMed  Google Scholar 

  40. Morales A, Chin JL, Ramsey EW (2001) Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol 166: 1633–1638

    Article  PubMed  Google Scholar 

  41. O’Donnell MA, Arnold J, de Boer EC et al. (1999) Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guerin. J Immunol 163: 4246–4252

    PubMed  Google Scholar 

  42. O’Donnell MA, Lilli K, Leopold C (2004) Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 172: 888–893

    Article  PubMed  Google Scholar 

  43. Poppas DP, Pavlovich CP, Folkman J et al. (1998) Intravesical bacille Calmette-Guerin induces the antiangiogenic chemokine interferon-inducible protein 10. Urology 52: 268–275

    Article  PubMed  Google Scholar 

  44. Prescott S, James K, Hargreave TB et al. (1990) Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 144: 1248–1251

    PubMed  Google Scholar 

  45. Prescott S, James K, Hargreave TB et al. (1992) Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 147: 1636–1642

    PubMed  Google Scholar 

  46. Pryor K, Stricker P, Russell P et al. (1995) Antiproliferative effects of bacillus Calmette-Guerin and interferon α2b on human bladder cancer cells in vitro. Cancer Immunol Immunother 41: 309–316

    PubMed  Google Scholar 

  47. Pryor K, Goddard J, Goldstein D et al. (1995) Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer 71: 801–807

    PubMed  Google Scholar 

  48. Ratliff TL, Shapiro A, Catalona WJ (1986) Inhibition of murine bladder tumor growth by bacille Calmette-Guerin: lack of a role of natural killer cells. Clin Immunol Immunopathol 41: 108–115

    Article  PubMed  Google Scholar 

  49. Ratliff TL, Palmer JO, McGarr JA, Brown EJ (1987) Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin. Cancer Res 47: 1762–1766

    PubMed  Google Scholar 

  50. Ratliff TL, Gillen DP, Catalona WJ (1987) Requirement of a thymus-dependant immune response for BCG- mediated antitumor activity. J Urol 137: 155–158

    PubMed  Google Scholar 

  51. Ratliff TL, Ritchey JK, Yuan JJJ et al. (1993) T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 150: 1018–1023

    PubMed  Google Scholar 

  52. Riemensberger J, Bohle A, Brandau S (2002) IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 127: 20–26

    Article  PubMed  Google Scholar 

  53. Saint F, Irani J, Salomon L et al. (2001) T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer. J Urol 166: 2142–2147

    Article  PubMed  Google Scholar 

  54. Saint F, Kurth N, Maille P et al. (2003) Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guerin response of superficial bladder cancer during induction course and maintenance therapy. Int J Cancer 107: 434–440

    Article  PubMed  Google Scholar 

  55. Shapiro A, Ratliff TL, Oakley DM, Catalona WJ (1983) Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Guérin and its correlation with bacillus Calmette-Guérin viability and natural killer cell activity. Cancer Res 43: 1611–1615

    PubMed  Google Scholar 

  56. Shin JS, Park JH, Kim JD et al. (1995) Induction of tumour necrosis factor-alpha (TNF-alpha) mRNA in bladders and spleens of mice after intravesical administration of bacillus Calmette-Guerin. Clin Exp Immunol 100: 26–31

    PubMed  Google Scholar 

  57. Soloway MS (1977) Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res 37: 2918–2929

    PubMed  Google Scholar 

  58. Suttmann H, Lehan N, Bohle A, Brandau S (2003) Stimulation of Neutrophil Granulocytes with Mycobacterium bovis Bacillus Calmette-Guerin Induces Changes in Phenotype and Gene Expression and Inhibits Spontaneous Apoptosis. Infect Immun 71: 4647–4656

    Article  PubMed  Google Scholar 

  59. Suttmann H (2004) Mechanisms of Bacillus Calmette-Guérin-mediated Natural Killer Cell activation. J Urol 172: 1490–1495

    Article  PubMed  Google Scholar 

  60. Sylvester RJ, van der Meijden AP, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168: 1964–1970

    Article  PubMed  Google Scholar 

  61. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K (2005) Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 174: 86–91

    Article  PubMed  Google Scholar 

  62. Thalmann GN, Dewald B, Baggiolini M, Studer UE (1997) Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression. J Urol 158: 1340–1344

    Article  PubMed  Google Scholar 

  63. Thalmann GN (2000) Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 164: 2129–2133

    Article  PubMed  Google Scholar 

  64. Thanhauser A (1993) Induction of bacillus-Calmette-Guerin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro. Cancer Immunol Immunother 37: 105–111

    Article  PubMed  Google Scholar 

  65. Thanhauser A (1995) The induction of bacillus-Calmette-Guerin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother 40: 103–108

    PubMed  Google Scholar 

  66. Watanabe E (2003) Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guerin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother 52: 481–486

    Article  PubMed  Google Scholar 

  67. Weiss GR (2003) Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. J Immunother 26: 343–348

    Article  PubMed  Google Scholar 

  68. Zhao W, Schorey JS, Bong-Mastek M et al. (2000) Role of a bacillus Calmette-Guerin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer 86: 83–88

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Keine Angaben

Author information

Authors and Affiliations

  1. Urologische Abteilung, HELIOS Agnes-Karll-Krankenhaus, Am Hochkamp 21, 23611, Bad Schwartau

    A. Böhle

  2. Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Homburg/Saar

    H. Suttmann

  3. Laborgruppe Immuntherapie, Forschungszentrum, Borstel

    S. Brandau

Authors
  1. A. Böhle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Suttmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Brandau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Böhle.

Additional information

Prof. Dr. A. Böhle: Vorstand der AUO, Sprecher der Organgruppe Blasentumor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Böhle, A., Suttmann, H. & Brandau, S. Wirkmechanismen der intravesikalen BCG-Immuntherapie des oberflächlichen Harnblasenkarzinoms. Urologe 45, 629–636 (2006). https://doi.org/10.1007/s00120-006-1059-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-006-1059-x

Schlüsselwörter

Keywords

Search

Navigation